Breaking News Headlines Today | Ground News

See every side of every news story

biopharmadive.com image

News from biopharmadive.com

The Ground News media bias check for biopharmadive.com is Center. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and AllSides.

biopharmadive.com’s aggregated factuality score is High. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about biopharmadive.com

Where is biopharmadive.com located?biopharmadive.com's Website

Media Bias Ratings

Average Bias Rating:

Center

Center

byMedia Bias/Fact Check

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top biopharmadive.com News

AstraZeneca sets out $15 billion China investment during Starmer visit — REUTERS / Yves Herman

AstraZeneca · United Kingdom

AstraZeneca sets out $15 billion China investment during Starmer visit

55% Center coverage: 22 sources

UK drugmaker AstraZeneca will invest $15 billion in China through 2030 to expand medicines manufacturing and research and development, it said on Thursday as British Prime Minister Keir Starmer visited Beijing.See the Story

Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

Obesity · United States

Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

86% Center coverage: 7 sources

NEW YORK--(BUSINESS WIRE)--Feb 3, 2026-See the Story

AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds

Diabetes · China

AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds

71% Center coverage: 7 sources

AstraZeneca’s deal with CSPC Pharmaceutical Group includes a Phase 1-ready obesity drug that hits the same targets as Eli Lilly’s obesity drug Zepbound, but with monthly dosing. The new collaboration builds on an existing drug R&D relationship between the two companies. The post AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds appeared first on MedCity News.See the Story

Breaking News Topics Related to biopharmadive.com